AQST · Aquestive Therapeutics, Inc.
$4.50
-0.10 (-2.07%)
At close · Aug 20
Market Cap
$564.17M
Shares
125.51M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.50
Open$4.61
Day$4.39–4.64
52W close$2.95–7.49
Avg vol 30d3.1M
Short int18.0M · 14.4% float · 8.9d
Short vol51%
Last earningsAug 12, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 8, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−0%
below
Price vs 50-day avg
+8%
above
RSI (14)
63
neutral
MACD trend
Positive
52-week position
34%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+19%
trailing
6-month return
+12%
trailing
YTD return
−30%
this year
Relative strength
+1%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+3% holders QoQ · +26 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.38% of float · ▲ +8.2% MoM · 8.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
186 holders — near 3-yr high, broad support
Squeeze score
94
high risk · 0–100
Fundamentals
Revenue growth
+1%
Y/Y
EPS growth
−53%
Y/Y
Free cash flow
$-53.0M
Balance sheet
$83.7M
net cash
Quant / Vol
risk profile
Volatility
85%
annualized · 1-yr
Max drawdown
−61%
past year
ATR
5.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Mar 4, 2026
end FY2026
Cash and cash equivalents
$70M
full year 2026
Total revenue
$46M – $50M
Prior guidance
period ended
· from the 8-K filed Nov 5, 2025
Total revenues
· 2025
$44M – $50M
Guided vs delivered
· last 3 settled
Total revenues
2025
guided $44M – $50M
$44.55M
In line
Total revenues
full year 2024
guided $48M – $51M
$57.56M
Beat +16.3%
Total revenues
full-year 2023
guided $47M – $50M
$50.58M
Beat +4.3%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−0%
Neutral
Price vs 50-day avg
+8%
Bullish
RSI (14)
63
Neutral
MACD trend
Positive
Bullish
52-week position
34%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+3% holders QoQ · +26 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.38% of float · ▲ +8.2% MoM · 8.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
186 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $4 · 34%
Range high $7
vs 200-day avg 0%
vs 50-day avg +8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash and cash equivalents | $98.5M | Ended Q2 2026 | — |
| doses manufactured | 48M | the second quarter 2026 | — |
| EPI MARKET TRX COUNT growth | 3.4% | Current 4 QTRs vs Prior 4 QTRs | — |
| Non-GAAP adjusted costs and expenses non-GAAP | 35.23M | Six Months Ended June 30, 2026 | — |
| Non-GAAP adjusted EBITDA non-GAAP | -6.97M | Six Months Ended June 30, 2026 | — |
| Non-GAAP adjusted EBITDA excluding Non-GAAP adjusted R&D expenses non-GAAP | 624K | Six Months Ended June 30, 2026 | — |
| Non-GAAP adjusted EBITDA loss non-GAAP | $5.2M | the second quarter 2026 | — |
| Non-GAAP adjusted manufacture and supply expenses non-GAAP | 7.16M | Six Months Ended June 30, 2026 | — |
| Non-GAAP adjusted selling, general and administrative expenses non-GAAP | $20.49M | Six Months Ended June 30, 2026 | — |
| Non-GAAP Gross Margin on total revenue non-GAAP | 75% | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AQST
this stock
Aquestive Therapeutics, Inc.
|
$564.17M | -30.4% | +0.8% | — | 14.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.85B | +16.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$50.24B | +1.7% | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.41B | -2.4% | — | — | 0.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AQST | +5.8% | +19.2% | +12.4% | +21.7% | -30.4% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +7.7% | +15.9% | +1.2% | +19.6% | -42.3% |
Key facts
CIK
1398733
CUSIP
03843E104
13F (30d)
178 filings
175 filers
Visit website
Investor relations